Laura Indolfi, CEO & Co-Founder of PanTher Therapeutics - "Target: Pancreatic Cancer"

Angel Invest Boston

Content provided by Sal Daher. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Sal Daher or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

5+ y ago 41:43

MP3•Episode home

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on April 26, 2024 14:16 (13d ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Accredited Investors, an Exciting Syndicate Is Under Way: Click to Learn More

Coming from a family of lawyers in Italy, Laura Indolfi was an unlikely candidate to found a tech startup. Yet, her love of engineering and fascination with materials took her to the storied labs at MIT led by Elazer Edelman and Bob Langer. Her startup, PanTher Therapeutics is using off-the-shelf cancer drugs and biomaterials to create a new way to treat cancers that are really hard to treat such as pancreatic cancer, Laura’s first target. Don’t miss this lively interview with a stellar founder.

Highlights include:

Laura Indolfi Bio
How Laura Indolfi Decided She Wanted to Be a Materials Engineer
Laura Indolfi Explains Why She Came to the US
“Like the first six months I was thinking of probably I will go back to Italy and probably join my family into the law firm. But once you pass that moment and you get adjusted to the space then it was much better.”
The Founding Story of PanTher Therapeutics
Business Mentors Have Been Very Helpful
Could MIT’s Process for Licensing Technology from the Institute’s Labs Be Improved?
What PanTher Is Doing and Why It Matters
“You end up with 12 times the cancer-killing drug on the tumor as you would get from intravenous application of the same drug.”
“We are planning to submit our final application to them [the FDA] beginning of next year, January 2019. That will allow us to start enrolling patients the first quarter of 2019.”
“The things that makes me as the CEO of the company very excited is the engagement from the clinical community. We had a partnership with clinical oncologists that they are operating on these patients, coming up to Boston to operate on the pigs.”
Sal Daher Reads a Review from a Listener and Asks for Your Review on iTunes
Laura’s Indolfi Advice on Fundraising
A Major Change at PanTher and What Drove It
Laura Indolfi’s Parting Thoughts
Arrigo Bodda, This Is for You

311 episodes

#Angelinvesting #Angelinvestor #Boston #Bostonstartups #Earlystagecompanies #Founders #Seedcapital #Seedfunding #Entrepreneur #Sal Daher #Venture Capital #Business #Trading